- Home
- CCIR vs ACIU Comparison
CCIR vs ACIU Comparison
Compare CCIR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIR
- ACIU
- Stock Information
- Founded
- CCIR 2021
- ACIU 2003
- Country
- CCIR United States
- ACIU Switzerland
- Employees
- CCIR N/A
- ACIU N/A
- Industry
- CCIR
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CCIR
- ACIU Health Care
- Exchange
- CCIR NYSE
- ACIU Nasdaq
- Market Cap
- CCIR 326.6M
- ACIU 270.1M
- IPO Year
- CCIR 2024
- ACIU 2016
- Fundamental
- Price
- CCIR $11.10
- ACIU $2.65
- Analyst Decision
- CCIR
- ACIU Strong Buy
- Analyst Count
- CCIR 0
- ACIU 2
- Target Price
- CCIR N/A
- ACIU $12.00
- AVG Volume (30 Days)
- CCIR 37.9K
- ACIU 203.0K
- Earning Date
- CCIR 01-01-0001
- ACIU 03-13-2025
- Dividend Yield
- CCIR N/A
- ACIU N/A
- EPS Growth
- CCIR N/A
- ACIU N/A
- EPS
- CCIR N/A
- ACIU N/A
- Revenue
- CCIR N/A
- ACIU $48,505,404.00
- Revenue This Year
- CCIR N/A
- ACIU $86.78
- Revenue Next Year
- CCIR N/A
- ACIU $118.22
- P/E Ratio
- CCIR N/A
- ACIU N/A
- Revenue Growth
- CCIR N/A
- ACIU 4097200.00
- 52 Week Low
- CCIR $9.98
- ACIU $2.25
- 52 Week High
- CCIR $12.20
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- CCIR N/A
- ACIU 47.51
- Support Level
- CCIR N/A
- ACIU $2.39
- Resistance Level
- CCIR N/A
- ACIU $2.74
- Average True Range (ATR)
- CCIR 0.00
- ACIU 0.14
- MACD
- CCIR 0.00
- ACIU 0.01
- Stochastic Oscillator
- CCIR 0.00
- ACIU 56.52
About CCIR COHEN CIRCLE ACQUISITION CORP I
Cohen Circle Acquisition Corp I is a blank check company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.